SAB Biotherapeutics (SABS) Stock: Buy, Sell, or Hold?
SABS - SAB Biotherapeutics, Inc. Common Stock
$3.41
-0.01 (-0.29%)
▼
5d:
-8.33%
30d:
-10.26%
90d:
+0.89%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When SABS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: SABS shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: SABS shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: SABS is currently trading at $3.41, which is considered oversold relative to its 30-day fair value range of $3.61 to $3.86.
Technical Outlook: Technically, SABS is showing sideways momentum. The price is currently testing key support at $3.38. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SABS scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.64 (+241.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SABS is showing sideways momentum. The price is currently testing key support at $3.38. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SABS scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.64 (+241.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.61 -
$3.86
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 241.2% below Wall St target ($11.64)
- WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.61 -
$3.86
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.38
Resistance Level
$3.99
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.57
Wall Street Target
$11.64
(+241.2%)
Revenue Growth (YoY)
-62.4%
Earnings Growth (YoY)
-60.0%
Share & Embed Analysis
Last updated: September 13, 2026 6:31 AM ET
Data refreshes hourly during market hours. Next update: 7:31 AM
Data refreshes hourly during market hours. Next update: 7:31 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SABS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
